EP1831210A1 — 8-aza-bicyclo[3.2.1]octane derivatives with an activity on chemokine ccr5 receptors
Assigned to Pfizer Ltd Great Britain · Expires 2007-09-12 · 19y expired
What this patent protects
The present invention provides compounds of formula (I) R3, (I) wherein R1, R2, R3 and R4 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be…
USPTO Abstract
The present invention provides compounds of formula (I) R3, (I) wherein R1, R2, R3 and R4 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.